Medicine and Health Sciences Commons^™

Obinutuzumab, A Potent Anti-B-Cell Agent, For Rituximab-Unresponsive Igm Anti-Mag Neuropathy., Goran Rakocevic, Ubaldo E. Martinez-Outshoorn, Marinos C. Dalakas

Department of Medical Oncology Faculty Papers

Anti-MAG demyelinating neuropathy is difficult to treat. All immunotherapies have failed except for rituximab, a chimeric B-cell–depleting monoclonal antibody against CD20, that helps up to 40% of patients based on 2 controlled and several uncontrolled series.^1,–,3 Because the majority of these patients are left disabled, stronger anti–B-cell agents might be promising.

We describe clinical response and autoantibody changes after treatment with obinutuzumab (Gazyva), a new generation of humanized anti-CD20 monoclonal antibodies, in 2 patients with anti-MAG neuropathy who continued to worsen despite multiple courses of rituximab. Obinutuzumab, approved for chronic lymphocytic leukemia (CLL), exerts greater peripheral and lymphoid B-cell …